Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Inhibition of DNA methylation promotes breast tumor sensitivity to netrin-1 interference.

Grandin M, Mathot P, Devailly G, Bidet Y, Ghantous A, Favrot C, Gibert B, Gadot N, Puisieux I, Herceg Z, Delcros JG, Bernet A, Mehlen P, Dante R.

EMBO Mol Med. 2016 Aug 1;8(8):863-77. doi: 10.15252/emmm.201505945. Print 2016 Aug.

2.

Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment.

Le Mercier I, Poujol D, Sanlaville A, Sisirak V, Gobert M, Durand I, Dubois B, Treilleux I, Marvel J, Vlach J, Blay JY, Bendriss-Vermare N, Caux C, Puisieux I, Goutagny N.

Cancer Res. 2013 Aug 1;73(15):4629-40. doi: 10.1158/0008-5472.CAN-12-3058. Epub 2013 May 30.

3.

Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.

Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier-Caux C, Caux C, Bendriss-Vermare N.

Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25.

4.

EMT inducers catalyze malignant transformation of mammary epithelial cells and drive tumorigenesis towards claudin-low tumors in transgenic mice.

Morel AP, Hinkal GW, Thomas C, Fauvet F, Courtois-Cox S, Wierinckx A, Devouassoux-Shisheboran M, Treilleux I, Tissier A, Gras B, Pourchet J, Puisieux I, Browne GJ, Spicer DB, Lachuer J, Ansieau S, Puisieux A.

PLoS Genet. 2012;8(5):e1002723. doi: 10.1371/journal.pgen.1002723. Epub 2012 May 24.

5.

CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues.

Sisirak V, Vey N, Vanbervliet B, Duhen T, Puisieux I, Homey B, Bowman EP, Trinchieri G, Dubois B, Kaiserlian D, Lira SA, Puisieux A, Blay JY, Caux C, Bendriss-Vermare N.

Blood. 2011 Nov 10;118(19):5130-40. doi: 10.1182/blood-2010-07-295626. Epub 2011 Sep 21.

6.

Induction of EMT by twist proteins as a collateral effect of tumor-promoting inactivation of premature senescence.

Ansieau S, Bastid J, Doreau A, Morel AP, Bouchet BP, Thomas C, Fauvet F, Puisieux I, Doglioni C, Piccinin S, Maestro R, Voeltzel T, Selmi A, Valsesia-Wittmann S, Caron de Fromentel C, Puisieux A.

Cancer Cell. 2008 Jul 8;14(1):79-89. doi: 10.1016/j.ccr.2008.06.005.

7.

[Dendritic cells and gliomas: a hope in immunotherapy?].

Jouanneau E, Poujol D, Caux C, Belin MF, Blay JY, Puisieux I; Club de Neuro-Oncologie de la Société Française de Neurochirurgie.

Neurochirurgie. 2006 Dec;52(6):555-70. Review. French.

PMID:
17203907
8.

TRF2 inhibition promotes anchorage-independent growth of telomerase-positive human fibroblasts.

Brunori M, Mathieu N, Ricoul M, Bauwens S, Koering CE, Roborel de Climens A, Belleville A, Wang Q, Puisieux I, Décimo D, Puisieux A, Sabatier L, Gilson E.

Oncogene. 2006 Feb 16;25(7):990-7.

PMID:
16205637
9.

Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model.

Jouanneau E, Poujol D, Gulia S, Le Mercier I, Blay JY, Belin MF, Puisieux I.

Cancer Immunol Immunother. 2006 Mar;55(3):254-67. Epub 2005 Aug 27.

PMID:
16133115
10.

IL-6 as an intracrine growth factor for renal carcinoma cell lines.

Alberti L, Thomachot MC, Bachelot T, Menetrier-Caux C, Puisieux I, Blay JY.

Int J Cancer. 2004 Sep 20;111(5):653-61.

11.

Canarypox virus expressing wild type p53 for gene therapy in murine tumors mutated in p53.

Odin L, Favrot M, Poujol D, Michot JP, Moingeon P, Tartaglia J, Puisieux I.

Cancer Gene Ther. 2001 Feb;8(2):87-98.

12.

[Cancer immunotherapy: new approaches].

Blay JY, Thomachot MC, Alberti L, Bachelot T, Voorzanger-Rousselot N, Puisieux I, Odin L, Ménétrier-Caux C.

Bull Cancer. 2000 Jan;87(1):97-106. Review. French. No abstract available.

13.

T-cell repertoire analysis in chronic plaque psoriasis suggests an antigen-specific immune response.

Bour H, Puisieux I, Even J, Kourilsky P, Favrot M, Musette P, Nicolas JF.

Hum Immunol. 1999 Aug;60(8):665-76.

PMID:
10439312
14.

[A balance of clinical trials in gene therapy].

Favrot MC, Coll JL, Puisieux I.

Bull Cancer. 1999 Jan;86(1):115-21. French. No abstract available.

15.

Application of gene transfer in cancer immunotherapy. From experimental data to clinical protocols.

Favrot MC, Puisieux I.

Adv Exp Med Biol. 1998;451:539-41. Review. No abstract available.

PMID:
10026924
16.

Canarypox virus-mediated interleukin 12 gene transfer into murine mammary adenocarcinoma induces tumor suppression and long-term antitumoral immunity.

Puisieux I, Odin L, Poujol D, Moingeon P, Tartaglia J, Cox W, Favrot M.

Hum Gene Ther. 1998 Nov 20;9(17):2481-92.

PMID:
9853515
17.

Can we define the mechanism of antitumor response observed during clinical adoptive immunotherapy?

Merrouche Y, Négrier S, Puisieux I, Favrot M.

J Natl Cancer Inst. 1997 Sep 17;89(18):1380. No abstract available.

PMID:
9308709
18.

Correlation between clinical response to interleukin 2 and HLA phenotypes in patients with metastatic renal cell carcinoma.

Bain C, Merrouche Y, Puisieux I, Blay JY, Negrier S, Bonadona V, Lasset C, Lanier F, Duc A, Gebuhrer L, Philip T, Favrot MC.

Br J Cancer. 1997;75(2):283-6.

19.
21.

T-cell repertoires in healthy and diseased human tissues analysed by T-cell receptor beta-chain CDR3 size determination: evidence for oligoclonal expansions in tumours and inflammatory diseases.

Even J, Lim A, Puisieux I, Ferradini L, Dietrich PY, Toubert A, Hercend T, Triebel F, Pannetier C, Kourilsky P.

Res Immunol. 1995 Feb;146(2):65-80.

PMID:
7481075
22.

Oligoclonality of tumor-infiltrating lymphocytes from human melanomas.

Puisieux I, Even J, Pannetier C, Jotereau F, Favrot M, Kourilsky P.

J Immunol. 1994 Sep 15;153(6):2807-18.

PMID:
8077684
23.

Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice.

Takahashi H, Nakada T, Puisieux I.

Science. 1993 Mar 5;259(5100):1460-3.

PMID:
8451642

Supplemental Content

Loading ...
Support Center